Stocktoria
Ceribell, Inc. CBLL
Nasdaq · XNAS · stock · Electromedical & Electrotherapeutic Apparatus · website · IPO 2024-10-11
Ceribell, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | $89.1M | $65.4M | $45.2M |
| Gross profit | $78.3M | $56.8M | $38.2M |
| R&D expense | $19.1M | $13.6M | $9.0M |
| Operating income | -$58.4M | -$39.7M | -$30.0M |
| Income tax | $0 | $0 | $11,000 |
| Net income | -$53.4M | -$40.5M | -$29.5M |
| EPS (diluted) | $-1.46 | $-3.39 | $-5.56 |
| Operating cash flow | -$40.8M | -$35.0M | -$29.2M |
| Free cash flow | -$41.6M | -$36.4M | -$30.1M |
| Cash & equivalents | $40.5M | $194.4M | $34.5M |
| Inventory | $7.3M | $6.9M | $5.9M |
| Total assets | $195.8M | $225.4M | $58.9M |
| Total liabilities | $40.5M | $34.2M | $23.8M |
| Shareholders' equity | $155.3M | $191.2M | -$112.3M |
Source: SEC EDGAR filings · CIK 0001861107 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.